Ascletis Pharma Stock Net Income
| ASCLF Stock | USD 2.10 0.12 6.06% |
As of the 11th of February 2026, Ascletis Pharma shows the risk adjusted performance of 0.1421, and Mean Deviation of 3.58. Ascletis Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascletis Pharma jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Ascletis Pharma is priced correctly, providing market reflects its regular price of 2.1 per share. Please also double-check Ascletis Pharma total risk alpha, which is currently at 0.4194 to validate the company can sustain itself at a future point.
Ascletis Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ascletis Pharma's valuation are provided below:Ascletis Pharma does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Ascletis |
Ascletis Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ascletis Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ascletis Pharma.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Ascletis Pharma on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Ascletis Pharma or generate 0.0% return on investment in Ascletis Pharma over 90 days. Ascletis Pharma is related to or competes with SanBio Company, CStone Pharmaceuticals, Pharming Group, Idorsia, SSY Group, Biogaia AB, and Tobii Dynavox. Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale... More
Ascletis Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ascletis Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ascletis Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 10.59 | |||
| Information Ratio | 0.1528 | |||
| Maximum Drawdown | 52.45 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 13.14 |
Ascletis Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascletis Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ascletis Pharma's standard deviation. In reality, there are many statistical measures that can use Ascletis Pharma historical prices to predict the future Ascletis Pharma's volatility.| Risk Adjusted Performance | 0.1421 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | 0.4194 | |||
| Sortino Ratio | 0.098 | |||
| Treynor Ratio | 0.8397 |
Ascletis Pharma February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1421 | |||
| Market Risk Adjusted Performance | 0.8497 | |||
| Mean Deviation | 3.58 | |||
| Semi Deviation | 3.63 | |||
| Downside Deviation | 10.59 | |||
| Coefficient Of Variation | 600.94 | |||
| Standard Deviation | 6.8 | |||
| Variance | 46.18 | |||
| Information Ratio | 0.1528 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | 0.4194 | |||
| Sortino Ratio | 0.098 | |||
| Treynor Ratio | 0.8397 | |||
| Maximum Drawdown | 52.45 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 13.14 | |||
| Downside Variance | 112.12 | |||
| Semi Variance | 13.14 | |||
| Expected Short fall | (11.87) | |||
| Skewness | 1.58 | |||
| Kurtosis | 9.31 |
Ascletis Pharma Backtested Returns
Ascletis Pharma appears to be dangerous, given 3 months investment horizon. Ascletis Pharma secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had a 0.12 % return per unit of standard deviation over the last 3 months. By analyzing Ascletis Pharma's technical indicators, you can evaluate if the expected return of 0.66% is justified by implied risk. Please makes use of Ascletis Pharma's risk adjusted performance of 0.1421, and Mean Deviation of 3.58 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Ascletis Pharma holds a performance score of 9. The firm shows a Beta (market volatility) of 1.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ascletis Pharma will likely underperform. Please check Ascletis Pharma's sortino ratio, semi variance, and the relationship between the information ratio and value at risk , to make a quick decision on whether Ascletis Pharma's price patterns will revert.
Auto-correlation | 0.08 |
Virtually no predictability
Ascletis Pharma has virtually no predictability. Overlapping area represents the amount of predictability between Ascletis Pharma time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ascletis Pharma price movement. The serial correlation of 0.08 indicates that barely 8.0% of current Ascletis Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.08 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Ascletis Pharma reported net income of (199.02 Million). This is 158.31% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is 134.86% higher than that of the company.
Ascletis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascletis Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ascletis Pharma could also be used in its relative valuation, which is a method of valuing Ascletis Pharma by comparing valuation metrics of similar companies.Ascletis Pharma is currently under evaluation in net income category among its peers.
Ascletis Fundamentals
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 116.15 M | |||
| Shares Outstanding | 1.09 B | |||
| Shares Owned By Insiders | 67.02 % | |||
| Shares Owned By Institutions | 1.94 % | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 7.61 X | |||
| Revenue | 76.88 M | |||
| Gross Profit | 39.17 M | |||
| EBITDA | (169.35 M) | |||
| Net Income | (199.02 M) | |||
| Cash And Equivalents | 2.5 B | |||
| Cash Per Share | 2.28 X | |||
| Total Debt | 2.75 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 28.93 X | |||
| Book Value Per Share | 2.50 X | |||
| Cash Flow From Operations | (146.93 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 315 | |||
| Beta | 0.81 | |||
| Market Capitalization | 672.93 M | |||
| Total Asset | 2.83 B | |||
| Net Asset | 2.83 B |
About Ascletis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascletis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascletis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascletis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.